Resultats de la cerca - David W. Cescon

Refinar resultats
  1. 1
    <i>APOBEC3B</i>expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation

    <i>APOBEC3B</i>expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation per David W. Cescon, Benjamin Haibe‐Kains, Tak W. Mak

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Seize the engine: Emerging cell cycle targets in breast cancer

    Seize the engine: Emerging cell cycle targets in breast cancer per Jesús Fuentes‐Antrás, Philippe L. Bédard, David W. Cescon

    Publicat 2024
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Evolution of the Randomized Controlled Trial in Oncology Over Three Decades

    Evolution of the Randomized Controlled Trial in Oncology Over Three Decades per Christopher M. Booth, David W. Cescon, Lisa Wang, Ian F. Tannock, Monika K. Krzyzanowska

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis

    Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis per Hadar Goldvaser, T. Barnes, Boštjan Šeruga, David W. Cescon, Alberto Ocaña, Domen Ribnikar, Eitan Amir

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    Invasive Pulmonary Aspergillosis Associated With Marijuana Use in a Man With Colorectal Cancer

    Invasive Pulmonary Aspergillosis Associated With Marijuana Use in a Man With Colorectal Cancer per David W. Cescon, Andrea Page, Susan E. Richardson, Malcolm J. Moore, Scott Boerner, Wayne L. Gold

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis

    Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis per Mustafa Al-Mubarak, Ariadna Tibau, Arnoud J. Templeton, David W. Cescon, Alberto Ocaña, Boštjan Šeruga, Eitan Amir

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review

    Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review per Laith Al-Showbaki, Brooke E. Wilson, Faris Tamimi, Consolación Moltó, Abhenil Mittal, David W. Cescon, Eitan Amir

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma

    NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma per David W. Cescon, Desmond She, Shingo Sakashita, Chang‐Qi Zhu, Melania Pintilie, Frances A. Shepherd, Ming‐Sound Tsao

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Ionizable Drugs Enable Intracellular Delivery of Co‐Formulated siRNA

    Ionizable Drugs Enable Intracellular Delivery of Co‐Formulated siRNA per Kai V. Slaughter, Eric N. Donders, Michael S. Jones, Sami G. Sabbah, Mitchell J. Elliott, Brian K. Shoichet, David W. Cescon, Molly S. Shoichet

    Publicat 2024
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Gene isoforms as expression-based biomarkers predictive of drug response in vitro

    Gene isoforms as expression-based biomarkers predictive of drug response in vitro per Zhaleh Safikhani, Petr Smirnov, Kelsie L. Thu, Jennifer Silvester, Nehmé El-Hachem, Rene Quevedo, Mathieu Lupien, Tak W. Mak, David W. Cescon, Benjamin Haibe‐Kains

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn’s disease

    A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn’s disease per William G. Newman, Xiangjun Gu, Richard F. Wintle, David W. Cescon, Mehrdad Yazdanpanah, Xiangdong Liu, Vanya Peltekova, Mark Van Oene, Christopher I. Amos, Katherine A. Siminovitch

    Publicat 2005
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

    Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts per Arvind Singh Mer, Wail Ba-Alawi, Petr Smirnov, Yi X. Wang, Ben Brew, Janosch Ortmann, Ming‐Sound Tsao, David W. Cescon, Anna Goldenberg, Benjamin Haibe‐Kains

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review

    Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review per Jessica Hopkins, David W. Cescon, Darren Tse, Penelope A. Bradbury, Wei Xu, Clement Ma, Paul Wheatley‐Price, John Waldron, David P. Goldstein, François Meyer, Isabelle Bairati, Geoffrey Liu

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  14. 14
    TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer

    TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer per Rebecca Dent, David W. Cescon, Thomas Bachelot, Kyung Hae Jung, Zhi‐Ming Shao, Shigehira Saji, Tiffany A. Traina, Petra Vuković, Darlington Mapiye, Micah J. Maxwell, Peter Schmid, Javier Cortés

    Publicat 2023
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent

    Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent per Jacqueline M. Mason, Dan Lin, Wei Xin, Yi Che, Yi Yao, Reza Kiarash, David W. Cescon, Graham C. Fletcher, Donald E. Awrey, Mark R. Bray, Guohua Pan, Tak W. Mak

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer

    Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer per Kelsie L. Thu, Jennifer Silvester, Mitchell J. Elliott, Wail Ba-Alawi, Meghan Duncan, Andrea C. Elia, Arvind Singh Mer, Petr Smirnov, Zhaleh Safikhani, Benjamin Haibe‐Kains, Tak W. Mak, David W. Cescon

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality

    Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality per Peter Lin, Corey Lourenco, Jennifer Cruickshank, Luís Palomero, Jenna E. van Leeuwen, Amy H.Y. Tong, Katherine Chan, Samah El Ghamrasni, Miguel Ángel Pujana, David W. Cescon, Jason Moffat, Linda Z. Penn

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer

    TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperabl... per Peter Schmid, Mafalda Oliveira, Joyce O’Shaughnessy, Massimo Cristofanilli, Stephanie L. Graff, Seock-Ah Im, Sherene Loi, Shigehira Saji, Shusen Wang, David W. Cescon, Tina Hovey, Agata Nawrot, KY Tse, Petra Vuković, Giuseppe Curigliano

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Functional variants of OCTN cation transporter genes are associated with Crohn disease

    Functional variants of OCTN cation transporter genes are associated with Crohn disease per Vanya Peltekova, Richard F. Wintle, Laurence A. Rubin, Christopher I. Amos, Qiqing Huang, Xiangjun Gu, William G. Newman, Mark Van Oene, David W. Cescon, Gordon R. Greenberg, Anne M. Griffiths, Peter St George‐Hyslop, Katherine A. Siminovitch

    Publicat 2004
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086

    Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 per Sherene Loi, Sylvia Adams, Peter Schmid, Javier Cortés, David W. Cescon, Eric P. Winer, Deborah Toppmeyer, Hope S. Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji Iwata, Ahmad Awada, Antoinette R. Tan, A. Wang, Gursel Aktan, Vassiliki Karantza, Roberto Salgado

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: